The Exciting Future of Probiotics in Treating Chronic Disease with Deanna Gibson, PhD | MGC Ep. 91
Inflammatory bowel diseases like ulcerative colitis remain among the most difficult chronic conditions to manage — but new science at the intersection of microbiome research and biotechnology may offer hope.In this episode of The Mind-Gut Conversation, I sit down with Dr. Deanna Gibson, microbiome researcher and cofounder of Melius Microbiomics, to explore how genetically engineered microbial medicines could transform the future of IBD treatment — and what it will take for patients and the medical community to embrace them.In this conversation, we explore:· How Dr. Gibson’s research led to the development of BioPersist™ and BioColonize™ for IBD.· Why new microbiome-targeted therapies are urgently needed — especially for younger patients in whom ulcerative colitis is on the rise.· What makes BioPersist™ different from traditional probiotics and current IBD treatments.· How genetically engineered microbial medicines (GEMMs) represent a new generation of gut therapies.· Early research findings that support BioPersist™ as a promising treatment for ulcerative colitis.· Challenges in gaining public trust for novel biotech therapies amid growing skepticism.· Exciting new discoveries in microbiome science — and the future potential for live biotherapeutics beyond IBD.If you’re curious about the exciting direction where gut health research is headed — and how the microbiome may change the way we treat chronic disease — this episode is for you.Tune in and join the conversation!Disclaimer: Dr. Mayer is the Chief Medical Officer of Melius Microbiomics and has been involved in the commercial development of Genetically Engineered Microbial Medicines (GEMMs).